sulforaphane has been researched along with Memory Disorders in 9 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
Memory Disorders: Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Okadaic acid (OKA) causes memory impairment and attenuates nuclear factor erythroid 2-related factor 2 (Nrf2) along with oxidative stress and neuroinflammation in rats." | 3.83 | Sulforaphane Ameliorates Okadaic Acid-Induced Memory Impairment in Rats by Activating the Nrf2/HO-1 Antioxidant Pathway. ( Dwivedi, S; Hanif, K; Nath, C; Rajasekar, N; Shukla, R, 2016) |
| "Sulforaphane is a type of organosulfur compound known as an isothiocyanate." | 1.62 | Sulforaphane enhances long-term potentiation and ameliorate scopolamine-induced memory impairment. ( Choi, GW; Choi, GY; Hwang, ES; Hwang, Y; Kim, BI; Kim, HB; Maeng, S; Park, H; Park, HS; Park, JH; Park, KS; Sul, JY, 2021) |
| "Sulforaphane is an herbal isothiocyanate enriched in cruciferous vegetables." | 1.48 | Sulforaphane Upregulates the Heat Shock Protein Co-Chaperone CHIP and Clears Amyloid-β and Tau in a Mouse Model of Alzheimer's Disease. ( Choi, BR; Han, JS; Kim, J; LaFerla, FM; Lee, KW; Lee, S; Park, JHY, 2018) |
| "Sulforaphane (SFN) is a natural compound that displays antioxidant and anti-inflammatory activities." | 1.42 | Sulforaphane rescues memory dysfunction and synaptic and mitochondrial alterations induced by brain iron accumulation. ( Aguzzoli, C; Bogo, MR; Dargél, VA; de Freitas, BS; de Lima, MN; Falavigna, L; Florian, PZ; Kist, LW; Köbe, LM; Lavich, IC; Piffero, B; Schröder, N, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, HJ | 1 |
| Jang, BK | 1 |
| Park, JH | 2 |
| Choi, JW | 1 |
| Park, SJ | 1 |
| Byeon, SR | 1 |
| Pae, AN | 1 |
| Lee, YS | 1 |
| Cheong, E | 1 |
| Park, KD | 1 |
| Kim, J | 5 |
| Park, HS | 1 |
| Hwang, ES | 1 |
| Choi, GY | 1 |
| Kim, HB | 1 |
| Park, KS | 1 |
| Sul, JY | 1 |
| Hwang, Y | 1 |
| Choi, GW | 1 |
| Kim, BI | 1 |
| Park, H | 1 |
| Maeng, S | 1 |
| Sunkaria, A | 1 |
| Bhardwaj, S | 1 |
| Yadav, A | 1 |
| Halder, A | 1 |
| Sandhir, R | 1 |
| Lee, S | 2 |
| Choi, BR | 2 |
| LaFerla, FM | 1 |
| Park, JHY | 1 |
| Han, JS | 2 |
| Lee, KW | 2 |
| Gao, J | 1 |
| Xiong, B | 1 |
| Zhang, B | 1 |
| Li, S | 1 |
| Huang, N | 1 |
| Zhan, G | 1 |
| Jiang, R | 1 |
| Yang, L | 1 |
| Wu, Y | 1 |
| Miao, L | 1 |
| Zhu, B | 1 |
| Yang, C | 1 |
| Luo, A | 1 |
| Seo, SG | 1 |
| Lavich, IC | 1 |
| de Freitas, BS | 1 |
| Kist, LW | 1 |
| Falavigna, L | 1 |
| Dargél, VA | 1 |
| Köbe, LM | 1 |
| Aguzzoli, C | 1 |
| Piffero, B | 1 |
| Florian, PZ | 1 |
| Bogo, MR | 1 |
| de Lima, MN | 1 |
| Schröder, N | 1 |
| Dwivedi, S | 1 |
| Rajasekar, N | 1 |
| Hanif, K | 1 |
| Nath, C | 1 |
| Shukla, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized,Double-blind, Placebo-controlled, Efficacy and Safety Study of Sulforaphane in Patients With Prodromal to Mild Alzheimer's Disease[NCT04213391] | 160 participants (Anticipated) | Interventional | 2020-05-10 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sulforaphane and Memory Disorders
| Article | Year |
|---|---|
Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Cell Line, Tumor; Disease Models, Ani | 2021 |
8 other studies available for sulforaphane and Memory Disorders
| Article | Year |
|---|---|
A novel chalcone derivative as Nrf2 activator attenuates learning and memory impairment in a scopolamine-induced mouse model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Cells, Cultured; Chalcone; Disease | 2020 |
Sulforaphane enhances long-term potentiation and ameliorate scopolamine-induced memory impairment.
Topics: Animals; Avoidance Learning; Hippocampus; Humans; Isothiocyanates; Long-Term Potentiation; Maze Lear | 2021 |
Sulforaphane attenuates postnatal proteasome inhibition and improves spatial learning in adult mice.
Topics: Animals; Animals, Newborn; CA3 Region, Hippocampal; Cell Line, Tumor; Dentate Gyrus; Gene Expression | 2018 |
Sulforaphane Upregulates the Heat Shock Protein Co-Chaperone CHIP and Clears Amyloid-β and Tau in a Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Cortex; Disease Models, Animal; Female; | 2018 |
Sulforaphane Alleviates Lipopolysaccharide-induced Spatial Learning and Memory Dysfunction in Mice: The Role of BDNF-mTOR Signaling Pathway.
Topics: Animals; Brain-Derived Neurotrophic Factor; Hippocampus; Inflammation; Isothiocyanates; Learning Dis | 2018 |
Sulforaphane alleviates scopolamine-induced memory impairment in mice.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Cells, Cultured; Choline O-Acetyltransferase; Female; | 2014 |
Sulforaphane rescues memory dysfunction and synaptic and mitochondrial alterations induced by brain iron accumulation.
Topics: Animals; Animals, Newborn; Anticarcinogenic Agents; Brain; Catalase; Disease Models, Animal; Dynamin | 2015 |
Sulforaphane Ameliorates Okadaic Acid-Induced Memory Impairment in Rats by Activating the Nrf2/HO-1 Antioxidant Pathway.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Survival; Glutamate-Cysteine Li | 2016 |